These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current status of antiangiogenic therapies for glioblastomas. Arrillaga-Romany I; Reardon DA; Wen PY Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142 [TBL] [Abstract][Full Text] [Related]
4. Angiogenic inhibition in high-grade gliomas: past, present and future. Jo J; Schiff D; Purow B Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175 [TBL] [Abstract][Full Text] [Related]
5. [Angiogenesis and anti-angiogenic strategies for glioblastoma]. de Boüard S; Guillamo JS Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Reardon DA; Wen PY Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Chinot OL Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106 [TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Simpson L; Galanis E Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364 [TBL] [Abstract][Full Text] [Related]
9. The role of avastin in the management of recurrent glioblastoma. Sweet JA; Feinberg ML; Sherman JH Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876 [TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633 [TBL] [Abstract][Full Text] [Related]
13. [Topics for antiangiogenic therapy for glioblastoma]. Takano S; Matsumura A No Shinkei Geka; 2012 Jun; 40(6):481-502. PubMed ID: 22647508 [No Abstract] [Full Text] [Related]
14. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Rose SD; Aghi MK Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504 [No Abstract] [Full Text] [Related]
15. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Hall WA; Vallera DA Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029 [TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Argyriou AA; Giannopoulou E; Kalofonos HP Oncology; 2009; 77(1):1-11. PubMed ID: 19439998 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme. Charalambous C; Chen TC; Hofman FM Neurosurg Focus; 2006 Apr; 20(4):E22. PubMed ID: 16709028 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis and invasion in malignant gliomas. Chi A; Norden AD; Wen PY Expert Rev Anticancer Ther; 2007 Nov; 7(11):1537-60. PubMed ID: 18020923 [TBL] [Abstract][Full Text] [Related]
19. Resistance to antiangiogenic therapies. Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752 [TBL] [Abstract][Full Text] [Related]
20. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Seystahl K; Weller M Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]